Global Human Immunoglobulin For Intramuscular Injection (IMIG) Market Growth 2025-2031

The global Human Immunoglobulin For Intramuscular Injection (IMIG) market size is predicted to grow from US$ 982 million in 2025 to US$ 1522 million in 2031; it is expected to grow at a CAGR of 7.6% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Human immunoglobulin for intramuscular injection (IMIG), commonly known as "IMIG", is an immunoglobulin preparation extracted and purified from healthy human plasma. It contains a variety of antibodies and is mainly used to enhance immunity. It is used by intramuscular injection and cannot be infused intravenously. Its functions include: 1. Prevention of infection: By providing antibodies against viruses (such as measles, hepatitis A, rubella, etc.) and bacteria, it helps prevent infections caused by these pathogens. 2. Replacement of xenogeneic blood products: Avoid the immune response caused by the use of animal blood products (such as horses, mice, etc.) to improve safety. 3. Treatment of immunodeficiency: Provide supplements for patients who cannot produce enough immunoglobulins on their own to help improve the function of the immune system.

United States market for Human Immunoglobulin For Intramuscular Injection (IMIG) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Human Immunoglobulin For Intramuscular Injection (IMIG) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Human Immunoglobulin For Intramuscular Injection (IMIG) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Human Immunoglobulin For Intramuscular Injection (IMIG) players cover Grifols, Pfizer, Octapharma, Takeda, Kedrion Biopharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Human Immunoglobulin For Intramuscular Injection (IMIG) Industry Forecast” looks at past sales and reviews total world Human Immunoglobulin For Intramuscular Injection (IMIG) sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Immunoglobulin For Intramuscular Injection (IMIG) sales for 2025 through 2031. With Human Immunoglobulin For Intramuscular Injection (IMIG) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Immunoglobulin For Intramuscular Injection (IMIG) industry.

This Insight Report provides a comprehensive analysis of the global Human Immunoglobulin For Intramuscular Injection (IMIG) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Immunoglobulin For Intramuscular Injection (IMIG) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Immunoglobulin For Intramuscular Injection (IMIG) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Immunoglobulin For Intramuscular Injection (IMIG) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Immunoglobulin For Intramuscular Injection (IMIG).

This report presents a comprehensive overview, market shares, and growth opportunities of Human Immunoglobulin For Intramuscular Injection (IMIG) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Children
Adult

Segmentation by Application:
Disease Prevention
Treatment
Diagnosis
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Grifols
Pfizer
Octapharma
Takeda
Kedrion Biopharma
CSL Behring
Tiantan Biological
Hualan Biological
Henjiu

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Immunoglobulin For Intramuscular Injection (IMIG) market?

What factors are driving Human Immunoglobulin For Intramuscular Injection (IMIG) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Human Immunoglobulin For Intramuscular Injection (IMIG) market opportunities vary by end market size?

How does Human Immunoglobulin For Intramuscular Injection (IMIG) break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver. Show more